4/27/2011 7:30 AM

Sweden in Focus for Indian Pharma Industry.......Pharma Online 18 April 2011

Sweden is very much on the map for Indian Pharma companies looking for innovation, research collaboration, European manufacturing, business development and licensing agreements. Read how Indian Pharma companies view Sweden as a Life Sciences destination in the article published in Pharma Online, and also the illustrative case study between Karo Bio of Sweden and Alkem Pharma of India

To Download the Complete Article(In Swedish Only) Click the below Link.......

Download the article

Karo Bio of Sweden and Alkem Pharma of India enter into an agreement for development of Eprotirome........Karo Bio Press Release 26 April 2011

Eprotirome a product for dyslipidemia (high blood fats) developed by Karo Bio of Sweden will now be jointly developed together with Alkem Pharma of India in venture that will see Alkem Pharma doing phase III trails for India, and also receiving licensing rights to market the product in India and other select developing markets. The co-operation between the companies will result in a cost saving of SEK 100mio from a total estimated level of SEK 400mio for Karo Bio by doing phase III trails in India.
 
Mumbai based Alkem Pharma is India's 7th largest pharma company is a FDA and MHRA, UK approved pharma company having a leadership position in anti-infection drugs. The company sells products in over 50 countries. Invest Sweden has facilitated this partnership under the guidance of its Senior Advisor and Head of Life Sciences, Dr. Sanjeevi Carani of Karlolinska Institut. Read all the details of how these type of collaborations that Invest Sweden works on helps companies in Sweden and India win-win.

To Read the Complete Press Release (In Swedish Only) Click the below Link.......

http://www.karobio.se/investormedia/pressreleaser/pressrelease?pid=565734